A61K 47/6875
The antibody being a hybrid immunoglobulin
Official title: {the antibody being a hybrid immunoglobulin}
A61K47/6875 (The antibody being a hybrid immunoglobulin) appears on 286 US grants and 517 published applications in this corpus.
Search patents in A61K- Granted patents
- 286
- Published applications
- 517
- Assignees
- 279
- Inventors
- 1,344
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 2 | 0 |
| 1992 | 1 | 0 |
| 1993 | 4 | 0 |
| 1994 | 2 | 0 |
| 1995 | 0 | 0 |
| 1996 | 5 | 0 |
| 1997 | 5 | 0 |
| 1998 | 4 | 0 |
| 1999 | 4 | 0 |
| 2000 | 3 | 0 |
| 2001 | 4 | 2 |
| 2002 | 3 | 9 |
| 2003 | 5 | 9 |
| 2004 | 4 | 7 |
| 2005 | 1 | 11 |
| 2006 | 5 | 10 |
| 2007 | 2 | 6 |
| 2008 | 6 | 13 |
| 2009 | 4 | 8 |
| 2010 | 8 | 9 |
| 2011 | 6 | 11 |
| 2012 | 6 | 13 |
| 2013 | 5 | 7 |
| 2014 | 11 | 24 |
| 2015 | 12 | 17 |
| 2016 | 14 | 19 |
| 2017 | 19 | 31 |
| 2018 | 5 | 22 |
| 2019 | 14 | 27 |
| 2020 | 14 | 23 |
| 2021 | 18 | 29 |
| 2022 | 12 | 25 |
| 2023 | 22 | 41 |
| 2024 | 18 | 34 |
| 2025 | 18 | 56 |
| 2026 | 19 | 54 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Compounds comprising a linker for increasing transcyclooctene stability25 Aug 2026US 12,714,752 B2Tagworks Pharmaceuticals B.V.
- Meditopes and meditope-binding antibodies and uses thereof25 Aug 2026US 12,714,753 B2City of Hope
- FGF21 compositions for treatment or prevention of neovascularization of the eye and methods therefor16 Jun 2026US 12,653,863 B2Children's Medical Center Corporation
- Combination of antibody-pyrrolobenzodiazepine derivative conjugate and PARP inhibitor9 Jun 2026US 12,648,946 B2Daiichi Sankyo Company, Limited
- Humanized anti-GPC-1 antibody2 Jun 2026US 12,643,955 B2Iwate Medical University
- Dual transporters and methods of use8 Oct 2026US 2026/0308269 A1Denali Therapeutics Inc.
- Immunoconjugates containing tnf-alpha and related methods and compositions thereof24 Sep 2026US 2026/0284216 A1Suzhou Fuse Biosciences Limited
- Site-specific orthogonal bioconjugate modality and application thereof24 Sep 2026US 2026/0286332 A1Genequantum Healthcare (Suzhou) Co., Ltd.
- Mutant of antibody variable region, and use thereof27 Aug 2026US 2026/0250416 A1
- Eribulin antibody-drug conjugates and methods of use20 Aug 2026US 2026/0241017 A1Eisai R&D Management Co., Ltd.
Most cited
By later US patents
- Chimeric antibody with specificity to human B cell surface antigen853US 5,500,362 AXoma Corporation · 1996
- Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells304US 5,789,554 AImmunomedics, Inc. · 1998
- Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells237US 6,187,287 B1Immunomedics, Inc. · 2001
- Chimeric antibody with specificity to human B cell surface antigen138US 5,677,180 AXoma Corporation · 1997
- Chimeric antibody with specificity to human B cell surface antigen120US 5,721,108 AXoma Corporation · 1998